L

LabCorp

Global life sciences R&D services

Executive Director, Technology Strategy & Value Management - Technology Strategy & Value Management

Full-TimeUpdated on 10/23/2026Deadline 12/1/26
$232k - $250k/yr
Expert
Bachelor's, Master's
Remote in USA+1 moreMore locations: Durham, NC, USA
RemoteApplicants within 35 miles of Burlington or Durham must work at least 3 days per week in the office; travel is approximately 20%.
Business & StrategyBusiness Operations

About the job

Requirements
  • A bachelor's degree is required; an equivalent combination of education and relevant experience may be considered.
  • At least 12 years of progressive experience in technology strategy, portfolio management, value management, technology business management, financial management, enterprise architecture, product or platform management, or related technology leadership disciplines.
  • At least 7 years of leadership experience, including responsibility for leading teams, functions, or enterprise-level capabilities within a large, complex organization.
  • Demonstrated experience developing and translating enterprise or technology strategy into actionable priorities, investment decisions, roadmaps, and measurable business outcomes.
  • Significant experience leading enterprise portfolio planning, investment governance, prioritization, capacity planning, or value-realization disciplines across a complex technology portfolio.
  • Demonstrated experience applying financial and investment-management principles to technology decisions, including business cases, total cost of ownership, investment analysis, benefits realization, and financial performance.
  • Experience influencing senior executives and leading cross-functional decision-making across Technology, Finance, Product, Architecture, and business organizations.
  • Demonstrated ability to lead large-scale organizational change, operating-model transformation, or implementation of new enterprise management disciplines and ways of working.
  • Experience operating with significant autonomy in a complex environment and balancing competing business priorities, financial constraints, technology considerations, and enterprise risks.
  • Strong executive communication and analytical capabilities, including translating complex business, financial, and technology information into recommendations for senior leadership.
  • Experience leading technology strategy, enterprise portfolio management, a Value Management Office, an Enterprise Portfolio Office, Technology Business Management, or similar enterprise capabilities within a large, complex organization.
  • Demonstrated experience managing or influencing significant technology investment portfolios and advising executives on investment prioritization, capital allocation, resource trade-offs, and value realization.
  • Experience designing or implementing product-, platform-, or value-stream-based operating and funding models, including transition from traditional project-based planning and governance.
  • Strong understanding of technology economics, including total cost of ownership, unit economics, cost transparency, investment modeling, benefits realization, and value-based decision-making.
  • Experience integrating enterprise architecture, modernization priorities, and technology roadmaps into strategic planning and investment governance.
  • Experience with enterprise portfolio management and Technology Business Management platforms such as Clarity, Apptio, or comparable technologies, including analytics and automation to improve portfolio intelligence and executive decision-making.
  • Experience applying artificial intelligence, advanced analytics, and intelligent automation to strategy, portfolio management, investment analysis, or enterprise management processes.
  • Relevant professional certifications or demonstrated expertise in Technology Business Management, portfolio management, product management, financial management, enterprise architecture, or organizational transformation.
  • Ability to travel approximately 20% as needed.
  • Strong understanding of modern enterprise technology, architecture, platforms, cloud, data, artificial intelligence, cybersecurity, and emerging technologies.
  • Ability to shape enterprise technology strategy, translate business priorities into technology and investment agendas, and align senior leaders around priorities and outcomes.
  • Deep understanding of enterprise portfolio management, investment prioritization, capacity allocation, governance, and resource optimization across complex technology portfolios.
  • Ability to evaluate technology investments, challenge assumptions, assess trade-offs, establish value frameworks, and connect technology spending to measurable business outcomes.
  • Ability to synthesize business, financial, operational, and technology information into insights, scenarios, and recommendations for executive decision-making.
  • Proven ability to design and lead organizational and operating-model change, including product-, platform-, and value-stream-oriented ways of working, funding models, governance, and decision rights.
  • Strong people leadership capabilities, including leading leaders, building high-performing teams, establishing accountability, developing talent, and creating an outcome- and value-oriented culture.
  • Ability to understand complex interdependencies, evaluate scenarios, anticipate implications, and make sound decisions in ambiguous environments.
  • Strong understanding of how technology enables business strategy and performance, balancing business needs with enterprise priorities, financial stewardship, technology sustainability, and long-term value.
  • A master's degree is preferred.
  • Experience in a highly regulated, global, or complex enterprise environment is preferred; healthcare, life sciences, diagnostics, or a related industry is preferred.
Responsibilities
  • Lead enterprise technology strategy and strategic planning, translating the CITO’s vision and enterprise priorities into a multi-year technology strategy, roadmap, and investment agenda.
  • Establish the annual strategic framework and priorities for Technology, aligning objectives, investment allocation, organizational capacity, and measurable business outcomes.
  • Align business strategy, technology priorities, architecture direction, product and platform roadmaps, and investment decisions across Technology leadership.
  • Connect strategy to execution through accountability linking strategic objectives, funded investments, value streams, executive ownership, and measurable outcomes.
  • Advise senior Technology and business leaders on priorities, investment alternatives, enterprise trade-offs, emerging capabilities, and transformation opportunities.
  • Establish and lead the Enterprise Portfolio Office, providing enterprise governance and transparency across technology investments, products, platforms, initiatives, capacity, dependencies, risks, and outcomes.
  • Own portfolio planning, including demand management, prioritization, investment planning, capacity allocation, optimization, and periodic replanning.
  • Define and evolve portfolio governance for a product- and platform-based operating model, including outcome-based decision frameworks and investment guardrails.
  • Lead executive portfolio and value reviews, providing actionable insight into performance, alignment, capacity, risks, dependencies, and resource-reallocation opportunities.
  • Orchestrate portfolio decision-making for senior Technology and enterprise governance forums, supporting investment decisions and trade-offs with business, financial, technology, and value considerations.
  • Establish and lead the Value Management Office framework, methodology, and governance, shifting focus from delivery outputs to measurable outcomes and realized value.
  • Define the enterprise benefits-realization framework and establish expected value for significant technology investments, measuring outcomes throughout and after the investment lifecycle.
  • Lead value engineering across the technology portfolio, challenging assumptions, scope, sequencing, and alternatives to improve return on investment, time-to-value, and outcomes.
  • Partner with business, product, platform, and value-stream leaders to embed value management in roadmaps, investment decisions, portfolio reviews, and funding decisions.
  • Own the enterprise technology business-case framework and set standards to evaluate, compare, approve, and measure significant technology investments.
  • Establish and lead the enterprise Technology Business Management discipline, connecting technology spending to services, products, platforms, value streams, capabilities, and outcomes.
  • Establish technology economic models, including total cost of ownership, unit economics, cost-to-serve, and build-versus-buy analysis, for evaluating technology and platform investments.
  • Lead investment analytics and scenario modeling to inform prioritization, resource allocation, capital decisions, and executive trade-offs.
  • Partner with Finance and Technology leadership to coordinate strategic planning, portfolio planning, financial planning, and investment allocation.
  • Drive financial transparency and accountability across the technology portfolio, giving senior leaders visibility into investment, consumption, performance, and realized value.
  • Lead the design and evolution of planning, portfolio, investment, and value-management disciplines for transition from project-based delivery to a product-, platform-, and value-stream-oriented operating model.
  • Establish value-stream planning and investment frameworks linking business capabilities and outcomes with technology products, platforms, capacity, funding, and accountability.
  • Define outcome-based funding and value-management mechanisms aligning persistent investment with measurable outcomes, delivery performance, and efficiency expectations.
  • Partner with Technology and business leaders to evolve capacity models, governance, funding mechanisms, decision rights, and management practices for the target operating model.
  • Identify and remove structural barriers to organizational agility, investment flexibility, speed-to-value, and accountability for business outcomes.
  • Provide leadership oversight for Enterprise Architecture and Technology Strategy, integrating architectural direction with strategy, portfolio planning, modernization priorities, and investment decisions.
  • Create mechanisms to translate business strategy, technology trends, and emerging capabilities into enterprise capability roadmaps and long-term technology direction.
  • Ensure architectural principles, standards, modernization priorities, and technology lifecycle considerations inform strategic planning and significant investment decisions.
  • Partner with Technology leaders to simplify the technology landscape, reduce technical debt, modernize strategic capabilities, increase reuse, and improve sustainability and economics.
  • Ensure architecture and investment governance balance near-term priorities with long-term technology health, scalability, resilience, and strategic flexibility.
  • Own strategy, governance, investment, and enterprise adoption of portfolio management capabilities and platforms, including Clarity and Mission Control.
  • Establish an authoritative enterprise source of portfolio intelligence spanning investments, strategic alignment, roadmaps, capacity, financials, dependencies, risks, decisions, and outcomes.
  • Define enterprise portfolio data standards, governance, and accountability to maintain accurate, timely, consistent, decision-useful information.
  • Advance artificial intelligence, intelligent automation, advanced analytics, and scenario modeling to improve portfolio intelligence, reduce administrative effort, identify risks and opportunities, and accelerate executive decisions.
  • Provide leadership for Corporate Business Relationship Management, strengthening strategic alignment between Technology and corporate functions.
  • Establish executive engagement, demand-management, and strategic planning practices connecting business priorities and capability needs to enterprise technology strategy and portfolio decisions.
  • Ensure business demand is challenged, shaped, prioritized, and evaluated against enterprise strategy, architecture, capacity, investment constraints, and expected value.
  • Build trusted relationships with senior business and Technology leaders and keep technology priorities and investments aligned with evolving business needs and enterprise objectives.
  • Serve as a senior advisor to Technology leadership on enterprise strategy, portfolio, investment, value, operating-model, and technology-economics decisions.
  • Lead and develop an organization spanning strategy, portfolio management, value management, Technology Business Management, architecture strategy, portfolio platforms, and business relationship management.
  • Influence decisions across Technology, Finance, business functions, Product, Engineering, Architecture, and other enterprise stakeholders, resolving competing priorities and driving alignment around enterprise outcomes.
  • Establish organizational objectives, decision rights, performance expectations, and accountability across assigned functions so they operate as an integrated enterprise management system.
  • Represent Technology in senior enterprise forums and with external partners, communicating strategy, investment priorities, portfolio performance, and technology value.
Desired Qualifications
  • A master's degree.
  • Experience operating within a highly regulated, global, or complex enterprise environment; healthcare, life sciences, diagnostics, or related industry experience is preferred.

About the company

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Get referred to LabCorp

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 30, 2026 Q2 revenue rose 5.8% and adjusted EPS rose 14.9%.
  • Sept. 10, 2026 management kept 2026 revenue guidance at $14.71-$14.83 billion.
  • Labcorp targets 5% to 8% annual revenue growth through 2029 after integrating MLM.

What critics are saying

  • CMS cuts lab reimbursement up to 15% from Jan. 1, 2027, crushing diagnostics margins.
  • Sept. 24, 2026 Labcorp accepted a $2.3 million multistate AMCA breach settlement and vendor controls.
  • Bedford, Massachusetts layoffs began Mar. 9, 2026, showing lab footprint rationalization and demand softness.

What makes LabCorp unique

  • Sept. 8, 2026 MLM acquisition gives Labcorp wholly owned labs across four continents.
  • Sept. 10, 2026 investor day framed Labcorp as diagnostics, biopharma, science, and technology.
  • Labcorp supported over 85% of FDA-approved new drugs and therapies in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • Unlimited Paid Time Off
  • Tuition Reimbursement
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Pulse 2.0
Oct 25th, 2026
Labcorp to acquire Millennium Health to expand toxicology testing

Labcorp has agreed to acquire Millennium Health, a specialty laboratory focused on drug testing and surveillance. The deal expands Labcorp's toxicology testing and its nationwide reach. Millennium Health has more than 15 years of experience helping clinicians track patients' use of prescription medications and illicit drugs. Its tests support the treatment of chronic pain, substance use disorders, and mental health conditions. Labcorp plans to combine Millennium's tools with its national laboratory network, digital capabilities, and patient service centres across the US. The companies expect easier test ordering and result delivery for customers. The deal is subject to regulatory approvals and customary closing conditions. "We are excited about how this acquisition by Labcorp will strengthen our ability" to serve communities, said Millennium chief executive officer Scott Walton.

PR Newswire
Oct 21st, 2026
Greenberg Traurig advises OPKO Health on $722M+ agreement to sell select BioReference Health assets to Labcorp.

Greenberg Traurig advises OPKO Health on $722M+ agreement to sell select BioReference Health assets to Labcorp. Oct 21, 2026, 14:35 ET MIAMI, Oct. 21, 2026 /PRNewswire/ - Global law firm Greenberg Traurig, P.A. advised OPKO Health, Inc., a multinational biopharmaceutical company, on its agreement to sell select assets of its wholly owned subsidiary, BioReference Health, LLC, to Labcorp. The purchase price for the transaction is $722 million in cash at closing, subject to an upward or downward adjustment based on closing business revenues, according to OPKO's press release. The agreement also provides for up to an additional $150 million earnout based on revenue from the 4Kscore(R) Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. The transaction is subject to regulatory approvals and customary closing conditions. As part of the agreement, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections, and certain operational assets, including more than 80 patient service centers. The Greenberg Traurig deal team was led by Miami Corporate Practice Co-Chair Drew M. Altman and Shareholder Guillaume Le Masson. Corporate Practice Shareholder Robert L. Grossman advised on the deal. Grossman is past chair of the firm's Israel practice, which he helped build and lead for more than 20 years. "We value our longstanding relationship with OPKO and appreciate the trust they placed in us on this transaction," said Corporate Practice Shareholder Robert L. Grossman, who advised on the deal. "This matter reflects the commitment, talent, and hard work of both the OPKO team and the multidisciplinary Greenberg Traurig lawyers who worked together across practices and offices." Other team members included Philadelphia Intellectual Property & Technology Associate Sukhdeep S. Gill; Miami Corporate Associate Ashelin Myus; Washington, D.C., Corporate Associate Macy K. Nix; and Miami Tax Associate Maria Walker. About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com. SOURCE Greenberg Traurig, LLP

Traders Agency
Oct 16th, 2026
Labcorp to acquire BioReference Health clinical, women's health and urology testing assets from OPKO for $722 million.

Labcorp to acquire BioReference Health clinical, women's health and urology testing assets from OPKO for $722 million. Traders Agency Team The Traders Agency editorial team delivers daily market anal... Follow Traders Agency on Google. Add Traders Agency, LLC as a preferred source so its market analysis shows up more in your Search and AI results. Labcorp and OPKO Health announced on October 15, 2026 that Labcorp has agreed to acquire select assets of BioReference Health, LLC, OPKO's wholly owned laboratory subsidiary, for $722 million in cash at closing, with the price subject to adjustment based on closing business revenues, plus up to an additional $150 million tied to future revenue from BioReference's 4Kscore prostate cancer test, according to a joint press release from the two companies. Deal terms and potential value. The $722 million cash component and the $150 million 4Kscore earnout together put the transaction's maximum potential value at $872 million, as reported by Medical Device Developments. Using the figures disclosed by the companies, its calculation shows the cash payment exceeds the earnout by $572 million ($722 million minus $150 million), or roughly 381% more than the contingent payment ((722 − 150) / 150 x 100). As an interpretation of that arithmetic, the upfront cash represents the bulk of the deal's value, with the earnout functioning as a smaller, performance-linked add-on; it is a comparison of the two disclosed amounts, not a forecast of what will ultimately be paid. Neither company's release specified the revenue thresholds or measurement period required to trigger the full $150 million 4Kscore earnout, nor did they disclose how the base $722 million price might be adjusted up or down based on BioReference's revenue at the time of closing. What Labcorp is acquiring. Labcorp will acquire BioReference's laboratory testing businesses focused on clinical and women's health testing services, urology, and diagnostic services provided to correctional institutions, along with certain operational assets including more than 80 additional patient service centers, per the joint announcement. Also included is BioReference's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. According to Medical Device Developments, the 4Kscore test secured FDA approval in 2021 after being available as a laboratory-developed test since 2014, and it assesses the probability of finding aggressive prostate cancer in men 45 or older with an age-stratified elevated PSA or a positive nodule on a digital rectal examination. The same outlet reported that OPKO's diagnostics segment generated $74.5 million in revenue in the second quarter, of which the 4Kscore test contributed $6.3 million, though the companies' releases did not break out what share of OPKO's overall diagnostics revenue or earnings the divested BioReference businesses represent, or what remains at OPKO after the deal closes. Rationale from both sides. OPKO Chairman and CEO Phillip Frost framed the sale as a step toward concentrating on drug development, saying, "This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business," according to the joint release. The statement did not specify how OPKO intends to deploy the cash proceeds, such as through debt reduction, pipeline funding or share repurchases. On Labcorp's side, Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp, said the acquisition "strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country," according to a PR Newswire version of the announcement. Labcorp expects the acquired business to generate approximately $250 million in revenue in the first year after close, based on its current post-closing forecasts, the companies said. Closing timeline and advisors. The transaction is subject to regulatory approvals and customary closing conditions. The companies said there will be no changes to operations or services and that both will continue to operate independently until closing; neither release specified an expected closing date. According to the joint release, Lazard is serving as Labcorp's financial advisor, with Hogan Lovells Cadwalader US LLP as lead transaction counsel and Parker Poe as real estate counsel. Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, with Greenberg Traurig P.A. as legal counsel. Analyst reaction. According to Yahoo Finance, Evercore ISI analysts said the deal fits Labcorp's strategy of expanding in higher-growth specialty testing, writing that "women's health strengthens the specialty offering, while 4Kscore adds a differentiated asset with an opportunity for broader distribution rather than simply more routine testing volume." William Blair analysts, cited in the same report, called the 4Kscore test a "particularly compelling asset" with opportunity for broader adoption, saying it could help identify patients for further evaluation and avoid unnecessary biopsies. These are the analysts' own characterizations and not independently verified projections. Bottom line. The agreement adds a defined set of clinical, women's health, urology and corrections testing operations plus the 4Kscore prostate test to Labcorp's network, with Labcorp projecting roughly $250 million in first-year revenue from the assets. The companies have not disclosed a closing date, the specific 4Kscore earnout thresholds, or how OPKO plans to use the proceeds, and both releases caution that timing, final purchase price and earnout outcomes remain subject to regulatory approval and other conditions outside either company's control. Related reading. DISCLAIMER: Traders Agency does not offer financial advice. The information provided is for educational purposes only and should not be considered financial advice. Traders Agency is not responsible for any financial losses or consequences resulting from the use of the information provided. Trading carries inherent risks and may not be suitable for all individuals. You are advised to conduct your own research and seek personalized advice before making any investment decisions, recognizing the potential risks and rewards involved. See more from Traders Agency on Google. Make Traders Agency, LLC a preferred source and its market analysis will appear more prominently in your Google Search, Top Stories, and AI results. The Traders Agency editorial team delivers daily market analysis, stock research, and trading education. Its team of analysts covers stocks, options, crypto, commodities, and macroeconomics to help traders make informed decisions. Join the Edge Stop watching. Start winning. 50,000+ traders get its daily brief before the market opens. Free. No spam. Unsubscribe anytime.

PR Newswire
Oct 15th, 2026
Labcorp enters into agreement with OPKO Health to acquire select assets of BioReference Health.

Labcorp enters into agreement with OPKO Health to acquire select assets of BioReference Health. Oct 15, 2026, 07:30 ET Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ - Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 additional patient service centers. As part of the agreement, Labcorp will also acquire BioReference Health's proprietary 4Kscore(R) Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision, making this important test more broadly available to patients across the country. When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, including a broad specialty testing menu, convenient patient service center network and robust data analytics and digital tools. "This acquisition strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By expanding our clinical, women's health, urology and corrections testing capabilities and broadening access to innovative diagnostics such as the FDA-approved 4Kscore Test, we can help providers make more informed decisions, improve patient care and increase access to the comprehensive laboratory services people need to live healthier lives." "This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "Labcorp's national scale and capabilities will broaden patient and provider access to BioReference's 4Kscore Test to many more patients across the country. We believe this transaction is an important catalyst to further unlock additional value for our shareholders." The purchase price for the transaction is $722 million in cash at closing, subject to an upward or downward adjustment (if any) based on closing business revenues, and up to an additional $150 million in an earnout based on revenue from the 4Kscore Test. Labcorp expects the business revenue to be approximately $250 million in the first year after close, based on Labcorp's current post-closing forecasts. This transaction is subject to regulatory approvals and customary closing conditions. Until the transaction closes, there will be no changes to operations or services, and both companies will continue to operate independently. Lazard is serving as Labcorp's financial advisor, Hogan Lovells Cadwalader US LLP is serving as lead transaction counsel and Parker Poe is serving as real estate counsel. Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, and Greenberg Traurig P.A. is serving as legal counsel. About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com. About OPKO OPKO Health, Inc. (Nasdaq: OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to (a) the anticipated impact of the transaction including expanding access to comprehensive, high-quality laboratory services, (b) increased access to testing services and expanded testing capabilities including with respect to the 4Kscore Test, (c) anticipated timing to closing, final purchase price, post-closing revenue, and earnout for the 4Kscore Test, (d) other anticipated potential benefits of the acquisition to Labcorp and OPKO Health, and (e) required regulatory approvals and customary closing conditions. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the control of Labcorp or OPKO Health. These factors, in some cases, have affected and in the future (together with other factors) could affect the ability of Labcorp or OKPO Health to implement its respective business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. Neither Labcorp nor OPKO Health has any obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in each of Labcorp's and OPKO Health's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the headings RISK FACTORS and MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, and in each of Labcorp's and OPKO Health's other filings with the SEC. SOURCE Labcorp Holdings Inc

PR Newswire
Oct 13th, 2026
Labcorp and Thrive Global launch Thrive 5 test pairing lab insights with daily habit coaching

Labcorp has launched the Thrive 5 Health Test, its first lab test developed with Arianna Huffington's behaviour change company, Thrive Global. The test is sold through Labcorp OnDemand. It measures five cardiometabolic indicators: ApoB, hs-CRP, HbA1c, blood pressure, and body mass index. Consumers book testing at select Labcorp patient service centres across the US. Results arrive through Labcorp's patient portal and MyLabcorp mobile app, along with educational content and Thrive Microsteps. These are small daily actions on food, movement, sleep, stress, and connection. "Too often, we get information about our health without guidance on what to do about it," said Huffington, Thrive Global's founder and chief executive officer.